Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of B019 Injection in patients with relapsed or refractory B-cell acute lymphoblast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• B019 Injection

Snippet

Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. | Conditions: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING